Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Palomar v. Alma Lasers

This article was originally published in The Gray Sheet

Executive Summary

Alma will pay royalties on past and future sales of its light-based hair removal systems to resolve patent infringement charges filed by Palomar in Massachusetts federal court. Palomar accused Alma's Harmony, Soprano, Soprano XL andSonata systems of infringing its '844 and '568 patents. "After a nine-month period at a slightly higher rate, Alma Lasers will pay a 7.5% ongoing royalty rate," Alma says. The firm also has agreed to change the appearance of its Harmony and Aria systems to avoid confusion with Palomar systems and will pay 11% for past patent and trade dress infringement. Cutera and Lumenis have settled similar cases with Palomar (1"The Gray Sheet" June 12, 2006, p. 12)...

You may also be interested in...

Cutera Settles Palomar Hair Removal Laser Suit For $22 Mil. Plus Royalties

Palomar plans to enforce its Anderson patents against additional makers of laser and lamp-based hair removal systems following a successful settlement June 5 with competitor Cutera for $22 mil. plus royalties

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts